Login
$ALKS
$46.53 -$0.50 (1.06%) Live

$ALKS SEC Filings

Filed On Filing
12 Nov 2026 8-K: Entry into a Material Definitive Agreement

On November 6, 2026, Alkermes, Inc. and Alkermes Pharma Ireland Limited (together, “Alkermes”), two wholly-owned indirect subsidiaries of Alkermes plc (the “Company”), entered into a Confidential Settlement and License Agreement (the “Se...

03 Nov 2026 Form 4: Gaffin David Joseph, EVP, CLO, Alkermes, Inc.

Sold 2,035 shares ($94K)

03 Nov 2026 144
03 Nov 2026 10-Q
03 Nov 2026 8-K: Results of Operations and Financial Condition

— GAAP Net Income of $16.3 Million and Adjusted EBITDA of $120.1 Million —

09 Oct 2026 Form 4: Reed Joshua, SVP, Chief Financial Officer

Received 9,164 shares by exercise or conversion · Gave up 4,069 shares to cover exercise price or tax ($163K)

09 Oct 2026 Form 4: Whitaker Anne Clem, Director

Granted 7,239 Restricted Stock Unit Award · Granted 17,998 Non Qualified Stock Option (Right to Buy)

02 Oct 2026 Form 4: Gaffin David Joseph, EVP, CLO, Alkermes, Inc.

Sold 2,034 shares ($83.5K)

02 Oct 2026 144
21 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

18 Sep 2026 Form 3: Whitaker Anne Clem, Director

No securities owned

16 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

DUBLIN, Sept. 16, 2026 — Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company’s Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive...

03 Sep 2026 Form 4: Gaffin David Joseph, EVP, CLO, Alkermes, Inc.

Sold 2,034 shares ($97.7K)

03 Sep 2026 144
01 Sep 2026 Form 4: Hopkinson Craig C., EVP R&D, Chief Medical Officer

Received 5,000 shares by exercise or conversion ($123K) · Sold 9,000 shares ($423K)

01 Sep 2026 144
17 Aug 2026 Form 4: Nichols Christian Todd, SVP, Chief Commercial Officer

Sold 7,576 shares ($373K)

17 Aug 2026 144
12 Aug 2026 8-K: Entry into a Material Definitive Agreement

This Amendment No. 1 to Credit Agreement, dated as of August 12, 2026 (this “Amendment”), to the Credit Agreement, dated as of February 12, 2026 (as amended, restated, supplemented or otherwise modified from time to time prior to the dat...

07 Aug 2026 Form 4: Jackson Blair Curtis, Director

Granted 217,534 Employee Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support